Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! 

China Clinical Trials 2017

Analysis of IND and NDA applications and approvals in China 2011-2017

Download free report on life science investment in China

Week in Review

Summaries of each week's events in China biotech are provided free to all readers.  A weekly email newsletter providing direct links to these articles is also available - click here for free email newsletter...

Week in Review: Tasly Biopharma Completes Pre-IPO Round at $1.9 Billion Valuation
Week in Review: Suzhou Innovent Files for HK IPO -- $500 Million Raise Rumored
Week in Review: CStone Acquires China Rights to Leukemia Drug in $424 Million Deal
Week in Review: CITIC Offers $3.6 Billion to Acquire China Biologic
Week in Review: Mevion Medical of Boston Closes $150 Million Financing from China Investors
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event

Device China 2018
September 8-9, 2018
SUZHOU,CHINA

http://www.devicechina.com.cn/